South Africa's 2026 GLP-1 Recall: How to Verify Semaglutide and Tirzepatide

What South African regulators reported

On 11 May 2026, the South African Health Products Regulatory Authority (SAHPRA) and South African Pharmacy Council (SAPC) inspected iDexis (Pty) Ltd, trading as Sentra Pharmacy, in Silverton, Pretoria. Their 23 May statement said injectable products were seized and alleged that semaglutide, tirzepatide and combination products were being produced and supplied beyond the legal limits of patient-specific compounding.³

The regulators reported illegal importation of active pharmaceutical ingredients, no analytical testing to confirm identity, potency and purity, inadequate conditions for sterile preparation, and no pharmacovigilance system. They also referred to adverse-event reports, including hospitalisations. These are regulator-reported inspection findings, not findings independently generated by Peptide South Africa.³

SAHPRA published the product recall on 22 May. On 8 July, SAHPRA, SAPC and the Health Professions Council of South Africa (HPCSA) jointly warned the public, pharmacies and dispensing practitioners against continued use, prescription or dispensing of the recalled iDEXIS products. The joint statement describes the action as a Class I, Type A recall and says the products pose a serious safety risk.^1,2

Exactly which names are covered?

The official warning names three product lines: iDEXIS Semaglutide, iDEXIS Tirzepatide, and iDEXIS Semaglutide/Tirzepatide. It does not say that every registered medicine containing semaglutide or tirzepatide is recalled. Recall status attaches to the named products and the details in SAHPRA's recall record, not to a molecule in the abstract.^1,2

Registered medicine, compounding and Section 21 are different routes

SAHPRA's current Section 21 guideline describes a controlled pathway for access to unregistered medicines for human use. Authorisation is application-specific and subject to regulatory conditions; it should not be inferred from a seller's website, a prescription alone or the presence of an analytical certificate.⁴

What a certificate of analysis can and cannot prove

A genuine, batch-linked laboratory report can be useful evidence about the tests actually performed on the submitted sample. Depending on the method, it may support an identity or purity claim. It does not, by itself, prove that the finished product is SAHPRA-registered, sterile, stable for the claimed shelf life, manufactured under an authorised quality system, clinically effective, correctly transported or suitable for a particular patient.

• Confirm that the batch number on the report exactly matches the batch on the package.
• Check the laboratory name, report identifier, test date, sample description and methods used.
• Distinguish identity or purity testing from sterility, endotoxin, potency, stability and finished-product release testing.
• Verify the report with the named laboratory when a verification link or contact channel is available.
• Treat the report as one piece of evidence—not as regulatory approval or a treatment recommendation.

A practical verification checklist for South Africans

1. Search the exact product name in SAHPRA's Registered Health Products resources or Medicines Online Directory; do not rely only on the active ingredient name.⁵
2. Check SAHPRA's current product-recall page and open the underlying notice for the exact name and available product details.⁶
3. Verify that the prescriber is registered with the HPCSA and that the supplying pharmacy or pharmacist appears in the SAPC register.⁷
4. Compare the package name, strength, dosage form, batch, expiry and supplier with the prescription and official product information. Ask the pharmacist to resolve any mismatch.
5. Be cautious when a seller substitutes a 'research' label, an analytical report or a low price for a verifiable regulatory and supply-chain record.
6. Do not continue using a product named in the recall. Contact the dispensing pharmacy and prescriber for product-specific instructions; seek urgent medical help for severe or rapidly worsening symptoms.

How the WHO's July 2026 statement fits

On 30 July 2026, World Health Organization safety advisory committees said GLP-1 receptor agonists have a positive benefit–risk balance when used for approved indications under qualified clinical supervision. The same statement warned that self-medication, unverified online sources and use without safety follow-up create preventable risk because identity, quality, purity and strength may not be assured.⁸

That distinction matters. Evidence supporting an approved medicine in a defined patient population does not validate an unregistered copy, a combination formulation, an unidentified powder or a self-directed protocol. Product identity, legal route, indication, manufacturing controls and clinical supervision are separate questions.

If you have an affected or suspicious product

• Do not use a product identified in the recall, and do not pass it to another person.
• Keep the container, packaging, receipt and any correspondence; they may be needed to identify the batch and supply route.
• Contact the dispensing pharmacy and prescribing clinician for instructions on return, replacement and clinical follow-up.
• Report a suspected adverse reaction through SAHPRA's Med Safety system. Both members of the public and healthcare practitioners can report.⁹
• Report suspected unlawful sale or distribution through SAHPRA's official reporting channels.